MedReg Intel

MDR 2017 Made Simple: Chapter XII – Miscellaneous & Transitional Provisions (Part 12 of 12) By Ankur K. Khare – Biomedical Engineer | AI Ethics & Medical Innovation Welcome to Part 12! You’ve reached the final part of the MDR 2017 Made Simple series. In this chapter, we bring together the “miscellaneous” and transitional provisions that quietly shape how MDR 2017 works in real life—old licenses, exemptions, record‑keeping, renewals, and how these rules connect to the future of device regulation in India. These aren’t flashy topics, but they decide whether your existing approvals stay valid, how you migrate to new formats, and how safe you are when rules evolve. Perfect for founders, regulatory professionals, and biomedical engineers who want long‑term regulatory stability, not just one‑time approvals. 1. Transitional Provisions: Moving from Old to New When MDR 2017 came into force, India already had devices approved under the older Drugs and Cosmetics Rules. Transiti...

MDR 2017 Made Simple: Chapter XI – Powers of Inspectors & Penalties Part 11 of 12 By Ankur K. Khare – Biomedical Engineer | AI Ethics & Medical Innovation Welcome to Part 11! Having navigated imports, recalls, and license management in Parts 8–10, we now explore the critical enforcement infrastructure that ensures MDR 2017 compliance in real operations. This chapter demystifies the powers of inspectors, inspection procedures, seizure authorities, and penalties that make MDR 2017 a living, enforceable regulation—not just a document on a shelf. This is where regulatory theory meets ground reality. Every biomedical engineer, startup founder, importer, and quality manager needs to understand how enforcement works, because a single inspection finding can cascade into queries, show-cause notices, license suspensions, and in severe cases, criminal prosecution with imprisonment. The stakes: Non-compliance discovered during inspection isn't just an operational hic...